Reinach, 15 April 2020 – At the Shareholders’ Annual General Meeting (AGM) of Evolva today all the proposals put forward by the Board of Directors were approved by the shareholders. Based on Article 6a of the COVID-19 Ordinance 2 of the Swiss Federal Council, the company asked its shareholders to vote through the independent proxy. The AGM was convened without the shareholders attending in person; 32,4% of the total 821`878`237 shares were represented.
For a detailed listing of all resolutions presented at the 2020 Annual general Meeting, please visit: https://www.evolva.com/investors/agm/
Evolva is a Swiss biotech company focused on the research, development and commercialization of products based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at www.evolva.com.
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
# # #
Head of Investor and Corporate Relations
+ 41 61 485 2003 (direct)
+ 41 79 739 2636 (mobile)